Stake logo

HARP

HARPOON THERAPEUTICS INC

About HARP

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Buy US stocks in Australia starting with HARP. Open an account and start investing today!

Market Capitalisation

$31.24M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

2.24M

High today

$1.19

Low today

$0.97

Open price

$0.99

52-week high

$6.20

52-week low

$0.59


HARP FAQs

One share of HARPOON THERAPEUTICS INC is valued at $1.15.

The ticker symbol for HARPOON THERAPEUTICS INC is HARP.

To buy HARP stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in HARP

As of 28/01/2023 HARPOON THERAPEUTICS INC has a market cap of $31M.

The HARPOON THERAPEUTICS INC 52-week high stock price is $6.20.

The HARPOON THERAPEUTICS INC 52-week low stock price is $0.59.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.